Sanofi makes $3.2 bln offer for US mRNA partner Translate Bio | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
June 04, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JUNE 04, 2025
Sanofi makes $3.2 bln offer for US mRNA partner Translate Bio

Global Economy

Reuters
03 August, 2021, 12:25 pm
Last modified: 03 August, 2021, 12:29 pm

Related News

  • Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
  • Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval
  • Beximco Pharma completes Sanofi acquisition
  • France's Sanofi halts work on mRNA Covid vaccine
  • Beximco Pharma inks Sanofi acquisition deal

Sanofi makes $3.2 bln offer for US mRNA partner Translate Bio

Translate Bio's shares surged on Monday following the Reuters report. Sanofi's offer of $38 represents a 30.4% premium to Translate Bio's August 2 closing price of $29.15

Reuters
03 August, 2021, 12:25 pm
Last modified: 03 August, 2021, 12:29 pm
The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. Photo: Reuters
The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. Photo: Reuters

Sanofi said on Tuesday it has made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the Covid-19 vaccine race, confirming a Reuters exclusive report.

Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio. The boards of both companies have approved the deal, it said.

"Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics," Sanofi Chief Executive Paul Hudson said in a statement.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Translate Bio's shares surged on Monday following the Reuters report. Sanofi's offer of $38 represents a 30.4% premium to Translate Bio's August 2 closing price of $29.15.

GROWING INTEREST IN MRNA TECHNOLOGY

Sanofi's bid for Translate Bio marks the latest interest by a large pharmaceutical company in mRNA technology, following its proven success in Covid-19 vaccines developed by Pfizer /BioNTech and Moderna.

The messenger RNA (ribonucleic acid) approach, an area of Translate Bio expertise, instructs human cells to make specific proteins that produce an immune response to a given disease.

Sanofi and Translate Bio have been working together since 2018 and joined forces last year to develop an mRNA-based Covid-19 vaccine. They expect interim results of their Phase I/II clinical trial in the third quarter.

The two companies are also looking at mRNA vaccines for several infectious diseases and in June started a Phase I trial evaluating a possible mRNA-based vaccine against seasonal influenza, building on Sanofi's expertise as one of the world's top flu vaccine makers.

TOUGH YEAR

Sanofi's interest comes after a tough year for the French drugmaker after falling behind rivals with less experience in the Covid-19 vaccine race, a major blow to CEO Paul Hudson who joined the company almost two years ago.

Sanofi warned last year its traditional, protein-based Covid-19 jab developed with GlaxoSmithKline showed an insufficient immune response in older people, delaying its launch until toward the end of 2021.

Hudson has also been under increasing pressure to reduce the company's dependence on its star eczema treatment Dupixent to boost earnings. Earlier this year, it agreed to fill and pack millions of doses of shots made by Pfizer/BioNTech, Johnson & Johnson and Moderna.

Translate Bio, set up in 2016, has not launched any drugs on the market but its clinical-stage pulmonary product using its mRNA platform is being tested as an inhaled treatment for cystic fibrosis in a Phase I/II clinical trial, its website says.

Top News / World+Biz

Sanofi

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Govt eases tax burden for company funds
  • Freedom fighters in training. Photo: Courtesy
    Govt revises definition of freedom fighter, recognising physicians, nurses who treated the wounded
  • A charging port is seen on a Mercedes Benz EQC 400 4Matic electric vehicle at the Canadian International AutoShow in Toronto, Ontario, Canada, 13 February 2019. REUTERS/Mark Blinch
    Electric vehicle gets incentive package for local manufacturing

MOST VIEWED

  • Representational Image. Photo: Collected
    400 electric buses to join Dhaka’s public transport network
  • Official seal of the Government of Bangladesh
    Govt raises special incentive for employees to 15% from July
  • From left, National Citizen Party Convener Nahid Islam, BNP Standing Committee member Salahuddin Ahmed talking to reporters in Dhaka on Monday, 2 June 2025. Photos: TBS
    BNP, NCP exchange got heated during Monday's meeting with CA Yunus
  • Budget FY26: Housing sector may take a hit, flat prices set to rise
    Budget FY26: Housing sector may take a hit, flat prices set to rise
  • Pie chart showing revenue sources (NBR tax, foreign grants, etc.) and bar graph showing expenditure breakdown by sector (public services, interest payments, education, etc.) for Bangladesh's FY26 budget.
    Budget FY26 in infographics
  • Infograph: TBS
    Is the revenue target realistic?

Related News

  • Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
  • Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval
  • Beximco Pharma completes Sanofi acquisition
  • France's Sanofi halts work on mRNA Covid vaccine
  • Beximco Pharma inks Sanofi acquisition deal

Features

Illustration: TBS

The GOAT of all goats!

1d | Magazine
Photo: Nayem Ali

Eid-ul-Adha cattle markets

1d | Magazine
Sketch: TBS

Budget FY26: What corporate Bangladesh expects

1d | Budget
The customers in super shops are carrying their purchases in alternative bags or free paper bags. Photo: Mehedi Hasan

Super shops leading the way in polythene ban implementation

1d | Panorama

More Videos from TBS

Tesla not interested in manufacturing cars in India, big blow to Modi government

Tesla not interested in manufacturing cars in India, big blow to Modi government

9h | TBS World
What are Europe's chances of global leadership once the shadow of the United States is lifted?

What are Europe's chances of global leadership once the shadow of the United States is lifted?

24m | Others
Signs of strain in India-Canada relations

Signs of strain in India-Canada relations

10h | TBS World
What police are doing to reduce sufferings on road and to ensure safety

What police are doing to reduce sufferings on road and to ensure safety

11h | Podcast
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net